Profil
David J.
Valacer worked as the Chief Medical Officer at Molecular Templates, Inc. and as a Principal at Weill Cornell Medical College.
He also briefly returned to Molecular Templates, Inc. as Chief Medical Officer in 2017.
Valacer holds a graduate degree from New York University and a doctorate from the University of Vermont College of Medicine.
Anciens postes connus de David J. Valacer
Sociétés | Poste | Fin |
---|---|---|
MOLECULAR TEMPLATES, INC. | Directeur Technique/Scientifique/R&D | 20/10/2017 |
Weill Cornell Medical College | Corporate Officer/Principal | - |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Directeur Technique/Scientifique/R&D | - |
Formation de David J. Valacer
New York University | Graduate Degree |
University of Vermont College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |